PHRM:CA:CNSX-PharmaTher Holdings Ltd (CAD)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.21

Change

-0.01 (-4.55)%

Market Cap

USD 0.02B

Volume

0.08M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

PharmaTher Holdings Ltd., a specialty pharmaceutical company, develops and commercialize specialty pharmaceuticals exhibiting the adoption and permitting novel delivery methods to enhance patient outcomes. The company's product pipeline includes KETARX, a ketamine hydrochloride injection for the treatment of Parkinson's disease, Amyotrophic Lateral Sclerosis, complex regional pain, and anesthesia and procedural sedation. It develops KETARX, a microneedle patch, for mental health, neurological, and pain disorders; and KETARX On-body pump for the maintenance of general anesthesia for diagnostic and surgical procedures. In addition, the company offers PHARMAPATCH, a microneedle patch technology solution, which includes hydrogel-forming and gelatin methacryloyl delivery system for the treatment of psychedelics and infectious diseases. Further, it has license agreement with BioRAE, Inc. for the development and commercialization of a novel biocompatible and biodegradable gelatin methacryloyl microneedle; and the University of Kansas to develop and commercialize the intellectual property of ketamine to treat ALS; as well as holds a patent and know-how license agreement with The Queen's University of Belfast to develop and commercialize hydrogel-forming microneedle patch delivery technology. The company was incorporated in 2019 and is headquartered in Toronto, Canada.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-07 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
DRUG:CA Bright Minds Biosciences Inc

+0.25 (+0.43%)

USD 0.38B
METX:CA METX

+0.05 (+1.25%)

USD 0.10B
GLAB:CA Gemina Laboratories Ltd

-0.08 (-10.26%)

USD 0.05B
ACOG:CA Alpha Cognition Inc.

N/A

USD 0.05B
DTC:CA Defence Therapeutics Inc

-0.03 (-4.41%)

USD 0.03B
MDMA:CA Pharmala Biotech Holdings Inc.

+0.01 (+1.69%)

USD 0.03B
DOSE:CA Rapid Dose Therapeutics Corp

N/A

USD 0.03B
TELI:CA Telescope Innovations Corp.

N/A

USD 0.02B
BIOV:CA BioVaxys Technology Corp

N/A

USD 0.01B
BETR:CA BetterLife Pharma Inc

+0.01 (+9.52%)

USD 0.01B

ETFs Containing PHRM:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -4.55% 33% F 27% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -4.55% 33% F 27% F
Trailing 12 Months  
Capital Gain -6.67% 50% F 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return -6.67% 50% F 65% D
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 13.27% 78% C+ 74% C
Dividend Return 13.27% 78% C+ 74% C
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 79.39% 38% F 29% F
Risk Adjusted Return 16.72% 88% B+ 75% C
Market Capitalization 0.02B 78% C+ 86% B+

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.